<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33961038</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2574-3805</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>4</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>May</Month>
              <Day>03</Day>
            </PubDate>
          </JournalIssue>
          <Title>JAMA network open</Title>
          <ISOAbbreviation>JAMA Netw Open</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Association of Low-Dose Quetiapine and Diabetes.</ArticleTitle>
        <Pagination>
          <StartPage>e213209</StartPage>
          <MedlinePgn>e213209</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e213209</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2021.3209</ELocationID>
        <Abstract>
          <AbstractText Label="IMPORTANCE">Quetiapine has been associated with increased risk of type 2 diabetes when used in medium or high doses for the treatment of severe mental disorders. It is not known whether low doses, commonly used off-label for sedative-hypnotic purposes, are also associated with increased risk of type 2 diabetes.</AbstractText>
          <AbstractText Label="OBJECTIVE">To investigate whether there is an association between prescription of low-dose quetiapine and the risk of type 2 diabetes.</AbstractText>
          <AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This cohort study examined nationwide Danish health registers for data regarding new users of quetiapine (n = 185 938) or selective serotonin reuptake inhibitors (SSRIs) (n = 1 031 920) who were aged 18 years or older between January 1, 1998, and December 31, 2018. Individuals with schizophrenia or bipolar disorder were excluded. Quetiapine-initiators were matched 1:1 with initiators of SSRIs, using a high-dimensional propensity score (hdPS). Maximum follow-up was 5 years. Association with cumulative dose was investigated, using a case-control approach nested among quetiapine users. Data analysis was performed from May to September 2020.</AbstractText>
          <AbstractText Label="EXPOSURES">Dispensing of quetiapine or SSRIs. Quetiapine prescriptions were limited to tablet strengths of 25 mg and 50 mg to focus on low-dose use.</AbstractText>
          <AbstractText Label="MAIN OUTCOMES AND MEASURES">Incident type 2 diabetes was defined as first filling of an antidiabetic medication, first register diagnosis of type 2 diabetes or first hemoglobin A1C measurement greater than or equal to 6.4% (≥48 mmol/mol). Incidence rates (IRs), incidence rate ratios (IRRs), and number-needed-to-harm (NNH) were calculated for full and matched cohorts using as-treated and intention-to-treat approaches. Odds ratios (ORs) were calculated for the association with cumulative quetiapine dose.</AbstractText>
          <AbstractText Label="RESULTS">Altogether, 896 285 patients were included in the full cohort; 538 164 (60%) were female and the median (interquartile range) age was 47 (33-67) years. There were 57 701 low-dose quetiapine initiators and 838 584 SSRI initiators. The matched cohort consisted of 54 616 pairs. In as-treated analyses, the incidence of type 2 diabetes during treatment with low-dose quetiapine (425 cases) was 9.59 cases/1000 person-years (PY) (95% CI, 8.72-10.5/1000 PY), which was slightly higher than for SSRI users (8462 cases; IR, 8.13/1000 PY; 95% CI, 7.96-8.30/1000 PY), resulting in a significant IRR of 1.18 (95% CI, 1.07-1.30) and NNH of 684 (95% CI, 418-1873). However, the between-group difference was nonsignificant in the hdPS-matched cohort (IR, 9.49 vs IR, 9.58; IRR, 0.99; 95% CI, 0.87-1.13). The case-control analysis found no dose-response association of low-dose quetiapine with diabetes (OR for doubling of the cumulative dose: 1.02; 95% CI, 0.95-1.09; P = .54), but in sensitivity analyses higher daily doses were associated with diabetes (all tablet strengths: OR, 1.08; 95% CI, 1.03-1.13).</AbstractText>
          <AbstractText Label="CONCLUSIONS AND RELEVANCE">In this cohort study, use of low-dose quetiapine was not associated with excess risk of type 2 diabetes in comparison with SSRIs.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Højlund</LastName>
            <ForeName>Mikkel</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Public Health, Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry Aabenraa, Mental Health Services in the Region of Southern Denmark, Aabenraa, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lund</LastName>
            <ForeName>Lars C</ForeName>
            <Initials>LC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Public Health, Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Andersen</LastName>
            <ForeName>Kjeld</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Research, Psychiatry, University of Southern Denmark, Odense, Denmark.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry Odense, Mental Health Services in the Region of Southern Denmark, Odense, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Correll</LastName>
            <ForeName>Christoph U</ForeName>
            <Initials>CU</Initials>
            <AffiliationInfo>
              <Affiliation>The Zucker Hillside Hospital, Department of Psychiatry, Zucker School of Medicine at Hofstra/Northwell, New York, New York.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hallas</LastName>
            <ForeName>Jesper</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Public Health, Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>05</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>JAMA Netw Open</MedlineTA>
        <NlmUniqueID>101729235</NlmUniqueID>
        <ISSNLinking>2574-3805</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>2S3PL1B6UJ</RegistryNumber>
          <NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003718" MajorTopicYN="N" Type="Geographic">Denmark</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057194" MajorTopicYN="N">Intention to Treat Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017367" MajorTopicYN="N">Serotonin Uptake Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Lund reported participation in research projects funded by Menarini Pharmaceuticals and LEO Pharma, all with funds paid to the institution where he was employed (no personal fees) outside the submitted work. Dr Correll has been a consultant and/or advisor to or has received honoraria from Acadia, Alkermes, Allergan, Angelini, Axsome, Gedeon Richter, Gerson Lehrman Group, Indivior, IntraCellular Therapies, Janssen/Johnson &amp; Johnson, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Medscape, Merck, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva; he provided expert testimony for Janssen and Otsuka; he served on a Data Safety Monitoring Board for Lundbeck, Rovi, Supernus, and Teva; he has received grant support from Janssen and Takeda; he is also a stock option holder of LB Pharma. Dr Hallas received a research grant from Novo Nordisk, unrelated to the current project. No other disclosures were reported.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>7</Day>
          <Hour>12</Hour>
          <Minute>49</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33961038</ArticleId>
        <ArticleId IdType="pmc">PMC8105749</ArticleId>
        <ArticleId IdType="doi">10.1001/jamanetworkopen.2021.3209</ArticleId>
        <ArticleId IdType="pii">2779687</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>U.S. Food and Drug Administration . SEROQUEL XR® (quetiapine fumarate) extended-release tablets. Accessed March 23, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022047s043lbl.pdf</Citation>
        </Reference>
        <Reference>
          <Citation>European Medicines Agency . Seroquel, Seroquel XR and associated names (quetiapine) - summary of product characteristics. Accessed March 23, 2020. https://www.ema.europa.eu/en/documents/referral/seroquel-seroquel-xr-associated-names-article-30-referral-annex-iii_en.pdf</Citation>
        </Reference>
        <Reference>
          <Citation>Hálfdánarson Ó, Zoëga H, Aagaard L, et al. . International trends in antipsychotic use: a study in 16 countries, 2005-2014. Eur Neuropsychopharmacol. 2017;27(10):1064-1076. doi:10.1016/j.euroneuro.2017.07.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.euroneuro.2017.07.001</ArticleId>
            <ArticleId IdType="pubmed">28755801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pringsheim T, Gardner DM. Dispensed prescriptions for quetiapine and other second-generation antipsychotics in Canada from 2005 to 2012: a descriptive study. CMAJ Open. 2014;2(4):E225-E232. doi:10.9778/cmajo.20140009</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.9778/cmajo.20140009</ArticleId>
            <ArticleId IdType="pmc">PMC4251508</ArticleId>
            <ArticleId IdType="pubmed">25485247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duncan D, Cooke L, Symonds C, Gardner D, Pringsheim T. Quetiapine use in adults in the community: a population-based study in Alberta, Canada. BMJ Open. 2016;6(3):e010861. doi:10.1136/bmjopen-2015-010861</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmjopen-2015-010861</ArticleId>
            <ArticleId IdType="pmc">PMC4809089</ArticleId>
            <ArticleId IdType="pubmed">27000788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marston L, Nazareth I, Petersen I, Walters K, Osborn DPJ. Prescribing of antipsychotics in UK primary care: a cohort study. BMJ Open. 2014;4(12):e006135. doi:10.1136/bmjopen-2014-006135</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmjopen-2014-006135</ArticleId>
            <ArticleId IdType="pmc">PMC4281533</ArticleId>
            <ArticleId IdType="pubmed">25524544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gjerden P, Bramness JG, Tvete IF, Slørdal L. The antipsychotic agent quetiapine is increasingly not used as such: dispensed prescriptions in Norway 2004-2015. Eur J Clin Pharmacol. 2017;73(9):1173-1179. doi:10.1007/s00228-017-2281-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00228-017-2281-8</ArticleId>
            <ArticleId IdType="pubmed">28623386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8(2):114-126. doi:10.1038/nrendo.2011.156</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrendo.2011.156</ArticleId>
            <ArticleId IdType="pubmed">22009159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holt RIG. Association Between Antipsychotic Medication Use and Diabetes. Curr Diab Rep. 2019;19(10):96. doi:10.1007/s11892-019-1220-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11892-019-1220-8</ArticleId>
            <ArticleId IdType="pmc">PMC6718373</ArticleId>
            <ArticleId IdType="pubmed">31478094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bobo WV, Cooper WO, Stein CM, et al. . Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry. 2013;70(10):1067-1075. doi:10.1001/jamapsychiatry.2013.2053</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamapsychiatry.2013.2053</ArticleId>
            <ArticleId IdType="pubmed">23965896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Correll CU, Joffe BI, Rosen LM, Sullivan TB, Joffe RT. Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study. World Psychiatry. 2015;14(1):56-63. doi:10.1002/wps.20187</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/wps.20187</ArticleId>
            <ArticleId IdType="pmc">PMC4329898</ArticleId>
            <ArticleId IdType="pubmed">25655159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ulcickas Yood M, Delorenze GN, Quesenberry CP Jr, et al. . Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose?
BMC Psychiatry. 2011;11(1):197. doi:10.1186/1471-244X-11-197</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-244X-11-197</ArticleId>
            <ArticleId IdType="pmc">PMC3264670</ArticleId>
            <ArticleId IdType="pubmed">22171594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carr CN, Lopchuk S, Beckman ME, Baugh TB. Evaluation of the use of low-dose quetiapine and the risk of metabolic consequences: A retrospective review. Ment Health Clin. 2016;6(6):308-313. doi:10.9740/mhc.2016.11.308</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.9740/mhc.2016.11.308</ArticleId>
            <ArticleId IdType="pmc">PMC6007538</ArticleId>
            <ArticleId IdType="pubmed">29955487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2010;25(suppl 2):S12-S21. doi:10.1016/S0924-9338(10)71701-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0924-9338(10)71701-6</ArticleId>
            <ArticleId IdType="pubmed">20620881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montastruc F, Palmaro A, Bagheri H, Schmitt L, Montastruc J-L, Lapeyre-Mestre M. Role of serotonin 5-HT2C and histamine H1 receptors in antipsychotic-induced diabetes: a pharmacoepidemiological-pharmacodynamic study in VigiBase. Eur Neuropsychopharmacol. 2015;25(10):1556-1565. doi:10.1016/j.euroneuro.2015.07.010</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.euroneuro.2015.07.010</ArticleId>
            <ArticleId IdType="pubmed">26256010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Application.
4th ed. Cambridge University Press; 2013.</Citation>
        </Reference>
        <Reference>
          <Citation>Langan SM, Schmidt SA, Wing K, et al. . The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ. 2018;363:k3532. doi:10.1136/bmj.k3532</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.k3532</ArticleId>
            <ArticleId IdType="pmc">PMC6234471</ArticleId>
            <ArticleId IdType="pubmed">30429167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holt RIG, Mitchell AJ. Diabetes mellitus and severe mental illness: mechanisms and clinical implications. Nat Rev Endocrinol. 2015;11(2):79-89. doi:10.1038/nrendo.2014.203</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrendo.2014.203</ArticleId>
            <ArticleId IdType="pubmed">25445848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pouwer F, Kupper N, Adriaanse MC. Does emotional stress cause type 2 diabetes mellitus? a review from the European Depression in Diabetes (EDID) Research Consortium. Discov Med. 2010;9(45):112-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20193636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14(2):119-136. doi:10.1002/wps.20204</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/wps.20204</ArticleId>
            <ArticleId IdType="pmc">PMC4471960</ArticleId>
            <ArticleId IdType="pubmed">26043321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kildemoes HW, Sørensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health. 2011;39(7)(suppl):38-41. doi:10.1177/1403494810394717</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1403494810394717</ArticleId>
            <ArticleId IdType="pubmed">21775349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health. 2011;39(7)(suppl):30-33. doi:10.1177/1403494811401482</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1403494811401482</ArticleId>
            <ArticleId IdType="pubmed">21775347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pedersen CB. The Danish Civil Registration System. Scand J Public Health. 2011;39(7)(suppl):22-25. doi:10.1177/1403494810387965</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1403494810387965</ArticleId>
            <ArticleId IdType="pubmed">21775345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmidt M, Schmidt SAJ, Adelborg K, et al. . The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol. 2019;11:563-591. doi:10.2147/CLEP.S179083</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/CLEP.S179083</ArticleId>
            <ArticleId IdType="pmc">PMC6634267</ArticleId>
            <ArticleId IdType="pubmed">31372058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>The Danish Health Data Authority . Medstat.dk (Register of Medicinal Product Statistics). Accessed February 19, 2020. https://medstat.dk/en</Citation>
        </Reference>
        <Reference>
          <Citation>Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20(4):512-522. doi:10.1097/EDE.0b013e3181a663cc</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/EDE.0b013e3181a663cc</ArticleId>
            <ArticleId IdType="pmc">PMC3077219</ArticleId>
            <ArticleId IdType="pubmed">19487948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083-3107. doi:10.1002/sim.3697</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/sim.3697</ArticleId>
            <ArticleId IdType="pmc">PMC3472075</ArticleId>
            <ArticleId IdType="pubmed">19757444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167(4):492-499. doi:10.1093/aje/kwm324</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/aje/kwm324</ArticleId>
            <ArticleId IdType="pubmed">18056625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flachs E, Eriksen L, Koch M, et al. . 
Sygdomsbyrden i Danmark - Sygdomme [Burden of Disease in Denmark]. Danish Health Authority; 2015.</Citation>
        </Reference>
        <Reference>
          <Citation>Campayo A, Gómez-Biel CH, Lobo A. Diabetes and depression. Curr Psychiatry Rep. 2011;13(1):26-30. doi:10.1007/s11920-010-0165-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11920-010-0165-z</ArticleId>
            <ArticleId IdType="pubmed">21052874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barnard K, Peveler RC, Holt RIG. Antidepressant medication as a risk factor for type 2 diabetes and impaired glucose regulation: systematic review. Diabetes Care. 2013;36(10):3337-3345. doi:10.2337/dc13-0560</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/dc13-0560</ArticleId>
            <ArticleId IdType="pmc">PMC3781547</ArticleId>
            <ArticleId IdType="pubmed">24065841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salvi V, Grua I, Cerveri G, Mencacci C, Barone-Adesi F. The risk of new-onset diabetes in antidepressant users - a systematic review and meta-analysis. PLoS One. 2017;12(7):e0182088. doi:10.1371/journal.pone.0182088</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0182088</ArticleId>
            <ArticleId IdType="pmc">PMC5536271</ArticleId>
            <ArticleId IdType="pubmed">28759599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manu P, Correll CU, van Winkel R, Wampers M, De Hert M. Prediabetes in patients treated with antipsychotic drugs. J Clin Psychiatry. 2012;73(4):460-466. doi:10.4088/JCP.10m06822</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4088/JCP.10m06822</ArticleId>
            <ArticleId IdType="pubmed">22225552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Højlund M, Pottegård A, Johnsen E, et al. . Trends in utilization and dosing of antipsychotic drugs in Scandinavia: comparison of 2006 and 2016. Br J Clin Pharmacol. 2019;85(7):1598-1606. doi:10.1111/bcp.13945</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bcp.13945</ArticleId>
            <ArticleId IdType="pmc">PMC6595354</ArticleId>
            <ArticleId IdType="pubmed">30927284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ndukwe HC, Nishtala PS. Glucose monitoring in new users of second-generation antipsychotics in older people. Arch Gerontol Geriatr. 2017;70:136-140. doi:10.1016/j.archger.2017.01.006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.archger.2017.01.006</ArticleId>
            <ArticleId IdType="pubmed">28131975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hinds A, Coulter L, Hudson J, Seaton V. Screening for diabetes in patients receiving second-generation atypical antipsychotics. Am J Health Syst Pharm. 2015;72(17)(suppl 2):S70-S73. doi:10.2146/ajhp150150</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2146/ajhp150150</ArticleId>
            <ArticleId IdType="pubmed">26272895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Connolly JG, Toomey TJ, Schneeweiss MC. Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011. Psychiatr Serv. 2015;66(6):604-609. doi:10.1176/appi.ps.201400222</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1176/appi.ps.201400222</ArticleId>
            <ArticleId IdType="pubmed">25726977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pillinger T, McCutcheon RA, Vano L, et al. . Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(1):64-77. doi:10.1016/S2215-0366(19)30416-X</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2215-0366(19)30416-X</ArticleId>
            <ArticleId IdType="pmc">PMC7029416</ArticleId>
            <ArticleId IdType="pubmed">31860457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gafoor R, Booth HP, Gulliford MC. Antidepressant utilisation and incidence of weight gain during 10 years’ follow-up: population based cohort study. BMJ. 2018;361:k1951. doi:10.1136/bmj.k1951</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.k1951</ArticleId>
            <ArticleId IdType="pmc">PMC5964332</ArticleId>
            <ArticleId IdType="pubmed">29793997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao S, Li J, Fan X, Liu Q, Lian J. The effect of selective serotonin re-uptake inhibitors on risk of type II diabetes mellitus and acute pancreatitis: a meta-analysis. Biosci Rep. 2018;38(5):BSR20180967. doi:10.1042/BSR20180967</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/BSR20180967</ArticleId>
            <ArticleId IdType="pmc">PMC6172426</ArticleId>
            <ArticleId IdType="pubmed">30126851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun JW, Hernández-Díaz S, Haneuse S, et al. . Association of selective serotonin reuptake inhibitors with the risk of type 2 diabetes in children and adolescents. JAMA Psychiatry. 2021;78(1):91-100. doi:10.1001/jamapsychiatry.2020.2762</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamapsychiatry.2020.2762</ArticleId>
            <ArticleId IdType="pmc">PMC7489393</ArticleId>
            <ArticleId IdType="pubmed">32876659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galling B, Roldán A, Nielsen RE, et al. . Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2016;73(3):247-259. doi:10.1001/jamapsychiatry.2015.2923</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamapsychiatry.2015.2923</ArticleId>
            <ArticleId IdType="pubmed">26792761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rubin DM, Kreider AR, Matone M, et al. . Risk for incident diabetes mellitus following initiation of second-generation antipsychotics among Medicaid-enrolled youths. JAMA Pediatr. 2015;169(4):e150285-e150285. doi:10.1001/jamapediatrics.2015.0285</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamapediatrics.2015.0285</ArticleId>
            <ArticleId IdType="pubmed">25844991</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
